Cargando…
250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Cystic Fibrosis Society.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527877/ http://dx.doi.org/10.1016/S1569-1993(22)00940-7 |
| _version_ | 1784801170971164672 |
|---|---|
| author | Dagenais, R. Su, V. Cen, R. |
| author_facet | Dagenais, R. Su, V. Cen, R. |
| author_sort | Dagenais, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9527877 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Cystic Fibrosis Society. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95278772022-10-03 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey Dagenais, R. Su, V. Cen, R. J Cyst Fibros Posters European Cystic Fibrosis Society. 2022-10 2022-10-03 /pmc/articles/PMC9527877/ http://dx.doi.org/10.1016/S1569-1993(22)00940-7 Text en Copyright © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Posters Dagenais, R. Su, V. Cen, R. 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey |
| title | 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey |
| title_full | 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey |
| title_fullStr | 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey |
| title_full_unstemmed | 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey |
| title_short | 250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey |
| title_sort | 250 dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: a practice survey |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527877/ http://dx.doi.org/10.1016/S1569-1993(22)00940-7 |
| work_keys_str_mv | AT dagenaisr 250dosingandtherapeuticdrugmonitoringofintravenousvancomycinincysticfibrosisapracticesurvey AT suv 250dosingandtherapeuticdrugmonitoringofintravenousvancomycinincysticfibrosisapracticesurvey AT cenr 250dosingandtherapeuticdrugmonitoringofintravenousvancomycinincysticfibrosisapracticesurvey |